Heng Mei

36PUBLICATIONS

31CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Genetics not elsewhere classifiedMolecular targetsPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (36)

Sort by Publication Date:

|Jul 14, 2026

Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.

|Apr 06, 2026

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

Nichola Cooper, Catherine M Broome, Yoshitaka Miyakawa

|Feb 24, 2026

Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.

Yan Xie, Ke-Shu Zhou, Lan-Fang Li

|Dec 23, 2025

The Novel HLA-A*02:1259 Allele, Identified by Sanger Dideoxy Nucleotide Sequencing in a Chinese Individual.

Yao-Gong Wu, Ming-Ming Wang, Yi-Bing Yang

|Nov 14, 2025

Integrin αvβ8-mediated TGF-β1 activation regulates the sustained response in immune thrombocytopenia after TPO-RA withdrawal.

Heng Mei, Min Xu, Jinhui Shu

|Oct 22, 2025

BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial.

Wenjing Luo, Yinqiang Zhang, Chenggong Li

Pageof 6

Frequent Collaborators

14 joint publications

Yu Hu

Huiwen Jiang

Fengjuan Fan

Eugenio Morelli

Hartmut Goldschmidt

Andreas Stadlbauer

Latifa Bakiri

Erwin F Wagner

Giovanni Tonon

Klaus Podar

Frequent Collaborators

14 joint publications

Yu Hu

3 joint publications

Huiwen Jiang

2 joint publications

Fengjuan Fan

2 joint publications

Eugenio Morelli